Compare prices and buy Selank from 39 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, CAS 129954-34-3) derived from the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) by C-terminal Pro-Gly-Pro extension for protease resistance. Preclinical studies link it to inhibition of enkephalin-degrading enzymes and to allosteric modulation of GABA binding in brain membranes, and small Russian trials compared it with benzodiazepines in anxiety disorders. Developed at the Russian Academy of Sciences' Institute of Molecular Genetics. Not FDA-approved.
For research purposes only. Not medical advice.
Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, CAS 129954-34-3. Its first four residues are tuftsin, an endogenous tetrapeptide at positions 289-292 of the CH2 domain of the immunoglobulin G heavy chain, reported by Najjar and Nishioka of Tufts University in 1970 and named after it. The trailing Pro-Gly-Pro was added to slow enzymatic breakdown.
That construction is the signature of one laboratory. Semax is built the same way, a short active fragment carrying the same Pro-Gly-Pro tail, and both came out of the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax vs Selank compares the two peptides' research records and FDA histories side by side.
Three mechanisms recur in the literature, supported at very different levels of evidence.
The controlled human data are entirely Russian, small, and published in Russian-language journals. Two studies in Zhurnal Nevrologii i Psikhiatrii set Selank against a benzodiazepine: Zozulya and colleagues against medazepam in 2008, Medvedev and colleagues against phenazepam in 2014. The 2008 study reported similar anxiolytic effects for the two drugs, and the 2014 study compared tolerability as well as effect.
As of October 2026, PubMed indexes no Selank trial from outside Russia and ClinicalTrials.gov lists no registered study. The FDA's Category 2 entry for Selank acetate cites a risk of immunogenicity from aggregation and peptide-related impurities, and says the agency lacks important information on its safety in humans.
Selank is registered in Russia as anxiolytic nasal drops, dispensed without a prescription, for anxiety states including neurasthenia and for stress-related disorders in adults, according to its Russian label as last revised in July 2025. Drugs@FDA lists no application for it, and it holds no United States approval for any indication.
In September 2023 the FDA placed a batch of peptides into Category 2 of the interim 503A bulk drug substances list, the category for substances it considers to raise significant safety risks, and Selank acetate, filed under its research designation TP-7, was one of them. In September 2024, the agency removed five of those substances. Four went because the parties that nominated them withdrew the nominations (AOD-9604, CJC-1295, ipamorelin acetate and thymosin alpha-1), and Selank acetate went after its nominator told the agency it intended to nominate a different bulk drug substance.
Selank was absent from the Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026, where seven peptides were heard and Semax was recommended for the 503A list by 8 votes to 5. A withdrawal does not by itself keep a substance from the committee, which heard the other four peptides from the 2024 removal later that year and heard Semax after its nomination was withdrawn in April 2026. As of October 2026 it has not heard Selank. The FDA's Category 2 page still lists Selank acetate, in its table of withdrawn nominations, with the same safety text, so the removal was administrative and left the agency's stated concern in place.
Its nomination had been withdrawn, and the FDA has not brought it to the committee on its own initiative. Selank acetate, listed as TP-7, was placed in Category 2 of the FDA's interim 503A bulk drug substances list in September 2023. In September 2024, the agency removed it after its nominator said it intended to nominate a different bulk drug substance, in the same update that removed AOD-9604, CJC-1295, ipamorelin acetate and thymosin alpha-1 on withdrawn nominations. A withdrawn nomination does not by itself rule out a hearing, and the Pharmacy Compounding Advisory Committee heard Semax on July 24, 2026 after its nomination was withdrawn that April. Semax, developed at the same institute by the same method, was recommended by 8 votes to 5. Selank was not among the seven peptides heard.
It is registered in Russia as anxiolytic nasal drops, sold without a prescription, for anxiety states including neurasthenia and for stress-related disorders in adults, and the clinical work behind that registration was done there. Drugs@FDA lists no application for it, it holds no United States approval for any indication, and it is not on the 503A bulks list that compounding pharmacies may draw from. Material sold by research vendors is offered for laboratory use only and not for human consumption.
No, the three are different molecules. Selank is the parent heptapeptide. N-Acetyl Selank, often sold as N-Acetyl Selank Amidate, adds an acetyl group at the N-terminus and an amide at the C-terminus, both blocking enzymes that trim peptides from the ends. Adalank is instead described by vendors as carrying an adamantane cage, and vendor pages and AI-written summaries frequently equate it with the acetylated amidated form, which is wrong. PeptideScouter indexes all three as separate rows, which keeps a per-milligram comparison like for like.
Two head-to-head comparisons against benzodiazepines, both in Zhurnal Nevrologii i Psikhiatrii. Zozulya and colleagues reported in 2008 on 30 patients given Selank against 32 given medazepam, in generalized anxiety disorder and neurasthenia. Medvedev and colleagues compared Selank with phenazepam in 60 patients with phobic anxiety and somatoform disorders in 2014, and examined the two in combination in 2015. These are small single-country studies published in Russian, and PubMed indexes no Selank trial from outside Russia.
Selank is sold by 39 research peptide vendors indexed on PeptideScouter, with 77 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
37 of the 39 indexed vendors currently have Selank in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Studz Peptides currently lists Selank at $2.10/mg, the lowest listed price across 39 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.89/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 39 vendors listing Selank publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.10/mg listed to $1.89/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Selank ranges from $2.10/mg to $8.90/mg across 77 listings from 39 research peptide vendors, normalized to USD per milligram and refreshed daily.
39 research peptide vendors currently list Selank on PeptideScouter, with 37 in stock right now. We track 77 listings across size and kit variants.
Selank's CAS Registry Number is 129954-34-3.
